Literature DB >> 22998346

Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation.

Naoki Kunii1, Yangbing Zhao, Shuguang Jiang, Xiaojun Liu, John Scholler, Lakshmi Balagopalan, Lawrence E Samelson, Michael C Milone, Carl H June.   

Abstract

It is likely that the enhancement of signaling after antigenic stimulation, particularly in the tumor microenvironment, would improve the function of adoptively transferred T cells. Linker for activation of T cells (LAT) plays a central role in T cell activation. We hypothesized that the ubiquitylation-resistant form of LAT in cells would enhance T cell signaling and thus augment antitumor activity. To test this, human CD4(+) or CD8(+) T cells were electroporated with small interfering RNA (siRNA) to repress endogenous LAT and ubiquitylation-resistant LAT 2KR or wild-type LAT mRNA was introduced for reexpression. Significantly enhanced phosphorylation of LAT and phospholipase C-γ (PLCγ) was observed, and augmented calcium signaling after T cell receptor (TCR) triggering was observed in LAT 2KR-expressing T cells. TCR-induced calcium signaling was abrogated in LAT knockdown cells, but the baseline was higher than that of control siRNA-electroporated cells, suggesting a fundamental requirement of LAT to maintain calcium homeostasis. Redirected LAT 2KR T cells expressing a chimeric antigen receptor or an MHC class I-restricted TCR showed augmented function as assessed by enhanced cytokine secretion and cytotoxicity. These results indicate that interruption of LAT ubiquitylation is a promising strategy to augment effector T cell function for adoptive cell therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22998346      PMCID: PMC3555093          DOI: 10.1089/hum.2012.130

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  40 in total

Review 1.  The TCR-mediated signaling pathways that control the direction of helper T cell differentiation.

Authors:  Toshinori Nakayama; Masakatsu Yamashita
Journal:  Semin Immunol       Date:  2010-05-21       Impact factor: 11.130

2.  Treatment of advanced leukemia in mice with mRNA engineered T cells.

Authors:  David M Barrett; Yangbing Zhao; Xiaojun Liu; Shuguang Jiang; Carmine Carpenito; Michael Kalos; Richard G Carroll; Carl H June; Stephan A Grupp
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

3.  Development and application of a multiplexable flow cytometry-based assay to quantify cell-mediated cytolysis.

Authors:  Lan-Feng Cao; Ludmila Krymskaya; Vivi Tran; Shu Mi; Michael C Jensen; Suzette Blanchard; Michael Kalos
Journal:  Cytometry A       Date:  2010-06       Impact factor: 4.355

4.  LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation.

Authors:  W Zhang; J Sloan-Lancaster; J Kitchen; R P Trible; L E Samelson
Journal:  Cell       Date:  1998-01-09       Impact factor: 41.582

5.  Functional nanoscale organization of signaling molecules downstream of the T cell antigen receptor.

Authors:  Eilon Sherman; Valarie Barr; Suliana Manley; George Patterson; Lakshmi Balagopalan; Itoro Akpan; Carole K Regan; Robert K Merrill; Connie L Sommers; Jennifer Lippincott-Schwartz; Lawrence E Samelson
Journal:  Immunity       Date:  2011-11-04       Impact factor: 31.745

6.  Decreased diacylglycerol metabolism enhances ERK activation and augments CD8+ T cell functional responses.

Authors:  Matthew J Riese; Jashanpreet Grewal; Jayajit Das; Tao Zou; Vineet Patil; Arup K Chakraborty; Gary A Koretzky
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

7.  Minimal requirement of tyrosine residues of linker for activation of T cells in TCR signaling and thymocyte development.

Authors:  Minghua Zhu; Erin Janssen; Weiguo Zhang
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

8.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors:  Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

9.  Ablation of Cbl-b provides protection against transplanted and spontaneous tumors.

Authors:  Jeffrey Y Chiang; Ihn Kyung Jang; Richard Hodes; Hua Gu
Journal:  J Clin Invest       Date:  2007-03-15       Impact factor: 14.808

10.  Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells.

Authors:  S Constant; C Pfeiffer; A Woodard; T Pasqualini; K Bottomly
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

2.  Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.

Authors:  A B Rodriguez-Peña; J Gomez-Rodriguez; R L Kortum; D C Palmer; Z Yu; G C Guittard; E A Wohlfert; P B Silver; J A Misplon; C L Sommers; L Feigenbaum; S L Epstein; R R Caspi; Y Belkaid; N P Restifo; L E Samelson; L Balagopalan
Journal:  Gene Ther       Date:  2015-06-18       Impact factor: 5.250

Review 3.  Roles of ubiquitination in the crosstalk between tumors and the tumor microenvironment (Review).

Authors:  Xiuzhen Zhang; Tong Meng; Shuaishuai Cui; Dongwu Liu; Qiuxiang Pang; Ping Wang
Journal:  Int J Oncol       Date:  2022-05-26       Impact factor: 5.884

4.  Effect of PLCε gene silencing on inhibiting the cancerous transformation of ulcerative colitis.

Authors:  Kun Yang; Jing Yan; Lan Peng; Yu-Pei Zou; Fu-Qian He; Hua-Tian Gan; Xiao-Li Huang
Journal:  Exp Ther Med       Date:  2016-04-15       Impact factor: 2.447

Review 5.  Regulating the discriminatory response to antigen by T-cell receptor.

Authors:  Kaustav Gangopadhyay; Swarnendu Roy; Soumee Sen Gupta; Athira C Chandradasan; Subhankar Chowdhury; Rahul Das
Journal:  Biosci Rep       Date:  2022-03-31       Impact factor: 3.840

6.  Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells.

Authors:  John Maher
Journal:  ISRN Oncol       Date:  2012-12-09

7.  Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

8.  Bypassing ubiquitination enables LAT recycling to the cell surface and enhanced signaling in T cells.

Authors:  Lakshmi Balagopalan; Hiba Malik; Katherine M McIntire; Joseph A Garvey; Tiffany Nguyen; Ana B Rodriguez-Peña; Lawrence E Samelson
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

Review 9.  RNA-electroporated T cells for cancer immunotherapy.

Authors:  Fernanda Pohl-Guimarães; Lan B Hoang-Minh; Duane A Mitchell
Journal:  Oncoimmunology       Date:  2020-10-07       Impact factor: 8.110

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.